Valuation: Spatializer Audio Laboratories, Inc.

Market Cap 5.45M 4.77M 4.4M 4.08M 7.75M 520M 7.85M 52.62M 20.48M 255M 20.46M 20.01M 885M P/E 2024
-0.28x
P/E 2025 -0.1x
Enterprise Value 772K 676K 622K 578K 1.1M 73.61M 1.11M 7.45M 2.9M 36.13M 2.9M 2.83M 125M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
-
Yield 2024 *
-
Yield 2025 -

Financials

2024 2025
Net sales - -
Net income -9.57M -8.39M -7.72M -7.17M -13.61M -913M -13.8M -92.46M -35.98M -448M -35.96M -35.17M -1.55B -8.77M -7.68M -7.08M -6.57M -12.47M -837M -12.64M -84.7M -32.96M -411M -32.94M -32.22M -1.42B
Net Debt -2.24M -1.96M -1.81M -1.68M -3.19M -214M -3.23M -21.64M -8.42M -105M -8.42M -8.23M -364M -4.68M -4.1M -3.77M -3.5M -6.65M -446M -6.74M -45.17M -17.58M -219M -17.57M -17.18M -759M
Logo Spatializer Audio Laboratories, Inc.
Enveric Biosciences Inc., formerly AMERI Holdings, Inc., is a patient-central biotechnology company. The Company is focused on enhancing lives of people affected by the side effects of cancer treatments, such as radiodermatitis and chemotherapy-induced peripheral neuropathy. The Company is engaged in leveraging its clinical developments derived from cannabinoids and taps into its global network of scientists and oncology physicians. The Company is advancing its pipeline of new-generation of naturally occurring and synthetic compounds. It is developing product candidates that target skin-related ailments common among cancer patients, including radiodermatitis, pruritus, rashes and dry skin, as well as indications such as chemotherapy-induced peripheral neuropathy, with future areas of focus that may include depression, pain and anxiety.
Employees
-
Sector
-